Specialised Therapeutics (ST) has entered an exclusive agreement to license Korea-based CanariaBio’s oregovomab for treating ovarian cancer.
The cancer therapy will be licensed for Australia, New Zealand and selected countries in South East Asia.
A monoclonal antibody, oregovomab is currently being analysed in a global Phase III clinical trial, the FLORA-5 study.
Oregovomab is being evaluated along with chemotherapy agents carboplatin and paclitaxel in advanced ovarian cancer patients.
The final results from the trial will be available in 2025.
ST will oversee the complete commercial, medical, regulatory and distribution works of oregovomab in Australia, Brunei, Malaysia, New Zealand, Singapore, Thailand and Vietnam.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
CanariaBio will also manage the production of the supply of the antibody to ST.
ST CEO Carlo Montagner stated: “ST has a portfolio of anti-cancer therapies targeting multiple solid tumours with the exception of ovarian cancer, and now oregovomab becomes our first ovarian cancer agent.
“Despite great advances in recent years, there remains a high unmet need in all our regions to treat this patient population. We look forward to working closely with our new partners at CanariaBio and pending the results of the pivotal Phase III registration study, making oregovomab available to eligible patients.”
According to the findings from a Phase II trial, treatment with oregovomab plus chemotherapy offered improvement in progression-free survival of almost 30 months versus chemotherapy alone.
In August 2023, ST licensed Treeway’s TW001 for the treatment of amyotrophic lateral sclerosis.